Advaxis, Inc. (ADXS) Engages SynCo Bio Partners for Manufact
Advaxis, Inc. (ADXS) Engages SynCo Bio Partners for Manufacturing of ADXS-HPV
Today before the opening bell, Advaxis, a biotechnology company developing the next generation of cancer immunotherapies, announced it had signed an agreement with SynCo Bio Partners to manufacture Advaxis’ leading drug candidate, ADXS-HPV. Under the terms of the agreement, SynCo Bio Partners will be assisting Advaxis in development of scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance and drug product.
As Advaxis’ lead immunotherapy for the treatment of HPV-associated cancers, ADXS-HPV showed strong increased survival and objective tumor responses in a Phase 2 trial featuring 110 patients with recurring cervical cancer. In this year, Advaxis plans to begin registrational trials for patient treatment of cervical cancer with ADXS-HPV.
“SynCo’s ability to manufacture both drug substance and drug product for ADXS-HPV will offer us increased flexibility as we expand our manufacturing process in preparation for commercial-scale production,” commented Daniel J. O’Connor, Chief Executive Officer of Advaxis. “To have the support of a world-class manufacturer, such as SynCo, is pivotal to our ability to make ADXS-HPV available to patients on a global scale, upon approval.”
Pierre Warffemius, Chief Executive Officer of SynCo Bio Partners, commented, “SynCo is very pleased to enter into a long-term manufacturing collaboration and looks forward to working with Advaxis to support global licensure of ADXS-HPV. Our leading position for supply of live microbial biopharmaceuticals, through providing high quality manufacturing services, will bring this therapeutic vaccine safely to patients for the treatment of HPV-associated cancers.”
For more information, visit: www.advaxis.com
Please read full disclaimers at https://disclaimer.missionir.com